Progression after First-Line Cyclin-Dependent Kinase 4/6 Inhibitor Treatment: Analysis of Molecular Mechanisms and Clinical Data

por Villa, Federica, Crippa, Alessandra, Pelizzoni, Davide, Ardizzoia, Alessandra, Scartabellati, Giulia, Corbetta, Cristina, Cipriani, Eleonora, Lavitrano, Marialuisa, Ardizzoia, Antonio
Publicado 2023

The role of mean corpuscular volume and red cell distribution width in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors: the MARECAP retrospect...

por Tommasi, Chiara, Scartabellati, Giulia, Giannarelli, Diana, Giorgi, Ugo De, Brighi, Nicole, Fornarini, Giuseppe, Rebuzzi, Sara Elena, Puglisi, Silvia, Caffo, Orazio, Kinspergher, Stefania, Mennitto, Alessia, Cattrini, Carlo, Santoni, Matteo, Verzoni, Elena, Rametta, Alessandro, Stellato, Marco, Malgeri, Andrea, Roviello, Giandomenico, Brunelli, Matteo, Buti, Sebastiano
Publicado 2023

The impact of proton-pump inhibitors administered with tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma

por Buti, Sebastiano, Tommasi, Chiara, Scartabellati, Giulia, De Giorgi, Ugo, Brighi, Nicole, Rebuzzi, Sara Elena, Puglisi, Silvia, Caffo, Orazio, Kinspergher, Stefania, Mennitto, Alessia, Cattrini, Carlo, Santoni, Matteo, Verzoni, Elena, Rametta, Alessandro, Stellato, Marco, Malgeri, Andrea, Roviello, Giandomenico, de Filippo, Massimo, Cortellini, Alessio, Bersanelli, Melissa
Publicado 2022